LUCD · Lucid Diagnostics Inc
AI read · Good for LUCD
The AI's read
Lucid posted Q2 revenue up 17% to $1.5M and ran 2,770 EsoGuard tests. They landed their first LBM coverage with Concert and are awaiting a Medicare draft LCD that management says could cover 40-50% of addressable market. The stock barely moved, down 0.8%, while RSI sits near 69. Cash of $33.4M plus $16.8M in recent proceeds offsets an $11.3M quarterly burn for now. Medicare coverage is binary and can meaningfully expand demand if favorable. We lean bullish because coverage and early commercial traction are fresh and not fully reflected in the share price, but execution and timing matter.